Changes strategically aligned to support planned launch of Anaphylm™ (dibutepinephrine) Sublingual Film, if approved by the FDA, and to accelerate the Company’s ongoing development initiatives Matthew ...
These Pennsylvania dishes carry the names of hidden towns, offering a tasty connection to the state’s lesser-known places.
Today, the Democrats in the Senate voted for the fourteenth time to shut down the government. People are going to be losing ...
Laws focused lowering drug prices have expanded in 15 states, with new boards and payment limits shaping affordability since 2017.
Verywell Health on MSN
More Price Cuts Are Coming for Diabetes Drugs. Here's What to Expect in 2026
Insulin costs have declined over the past two years, and additional price cuts are expected in 2026. Medicare will lower prices for several diabetes drugs, including Januvia and Jardiance. Federal and ...
Research and development (R&D) expenses were $40.2 million for the third quarter of 2025, compared to $45.4 million for the comparable period in 2024. The decrease was primarily related to the ...
We're continuing to build out and training of our dedicated PONVORY sales force team ... of Fanapt in bipolar disorder and ...
VAMC has developed strong QI programs for hospitalists, emphasizing research, education, and collaboration to enhance veteran care. These initiatives include training chief residents in QI, supporting ...
Complex on MSN
MacKenzie Scott Gifts $80M to Howard University
Scott's donation follows her $63 million gift to Morgan State University, which was the largest in the HBCU's history.
On a bright, sunny evening in August, SG Ellison, CEO of franchisee organization Diversified Restaurant Group (DRG), walks ...
Jacksonville Journal-Courier on MSN
Jacksonville Memorial Hospital at 150 years: How it has gone from humble beginnings to being a healthcare leader in region
From 1875 to today, Jacksonville Memorial Hospital has grown with its community, earning Magnet status and expanding access to quality health care.
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results